Compile Data Set for Download or QSAR
Report error Found 66 of ic50 for UniProtKB: Q13490
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298445(US10125100, Example 42 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 3nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM337707(US9751837, Example 17(am) | US10392346, Example 17...)
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298449(US10125100, Example 47 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298426(US10125100, Example 17(af) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298439(US10125100, Example 22 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298442(US10125100, Example 39 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298436(US10125100, Example 19 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 8nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298425(US10125100, Example 17(ae) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298392(US10125100, Example 14 | 4-[[4-[[4-[[5-tert-Butyl-...)
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM255476(US9499486, 1 | US10125100, Example 1 | US9751837, ...)
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298441(US10125100, Example 36 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 19nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298375(US10125100, Example 2 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298421(US10125100, Example 17(aa) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298410(US10125100, Example 17(p) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298404(US10125100, Example 17(j) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 21nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298390(US10125100, Example 12 | 1-[5-tert-Butyl-3-(methan...)
Affinity DataIC50: 23nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298407(US10125100, Example 17(m) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 25nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298450(US10125100, Example 48 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 29nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298444(US10125100, Example 41 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 31nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298394(US10125100, Example 16 | 4-[[4-[[4-[[5-tert-Butyl-...)
Affinity DataIC50: 34nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412165(US10398702, Example 4 | N-(4-(((S)-3-((2,6- difluo...)
Affinity DataIC50: 34.7nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412169(US10398702, Example 8 | (3S)-N-[2-[[(3S)-3-[(2,6- ...)
Affinity DataIC50: 34.8nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412183(US10398702, Example 22 | tert-Butyl (2R,5S)-4-[2-[...)
Affinity DataIC50: 35nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298386(US10125100, Example 11 | N-(5-(tert-Butyl)-2-metho...)
Affinity DataIC50: 35nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298447(US10125100, Example 45 | N-(5-(tert-Butyl)-3-(3-(4...)
Affinity DataIC50: 36nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298440(US10125100, Example 26 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 40nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298434(US10125100, Example 17(cm) | 4-((4-((4-(3-(5-(tert...)
Affinity DataIC50: 47nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298396(US10125100, Example 17(b) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 52nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298382(US10125100, Example 7 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 59nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412182(US10398702, Example 21 | tert-Butyl (2R,5S)-4-[2-[...)
Affinity DataIC50: 60nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298393(US10125100, Example 15 | 4-[[4-[[4-[[5-tert-Butyl-...)
Affinity DataIC50: 64nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298415(US10125100, Example 17(u) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 66nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412163(US10398702, Example 2 | N-(2-(((S)-3-((2,6- difluo...)
Affinity DataIC50: 72.1nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412173(US10398702, Example 12 | (R)-N-((S)-3-((2,6- diflu...)
Affinity DataIC50: 105nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412168(US10398702, Example 7 | N1-((S)-3-((2,6- difluorop...)
Affinity DataIC50: 107nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412181(US10398702, Example 20 | (S)-N-(2-(((S)-3-((2,6- d...)
Affinity DataIC50: 110nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298416(US10125100, Example 17(v) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 116nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412179(US10398702, Example 18 | tert-Butyl (2R,5S)-4-[2-[...)
Affinity DataIC50: 116nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298380(US10125100, Example 5 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 119nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298412(US10125100, Example 17(r) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 119nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298379(US10125100, Example 4 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 121nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298381(US10125100, Example 6 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 137nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298405(US10125100, Example 17(k) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 156nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298443(US10125100, Example 40 | N-(5-(tert-Butyl)-3-(3-(4...)
Affinity DataIC50: 162nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412176(US10398702, Example 15 | tert-Butyl (2R,5S)-4-[2-[...)
Affinity DataIC50: 177nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412162(US10398702, Example 1 | N-((S)-3-((2,6- difluoroph...)
Affinity DataIC50: 178nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412170(US10398702, Example 9 | (3R)-N-[2-[[(3S)-3-[(2,6- ...)
Affinity DataIC50: 182nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298384(US10125100, Example 9 | N-(5-(tert-Butyl)-3-(3-(4-...)
Affinity DataIC50: 197nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM412178(US10398702, Example 17 | tert-Butyl N-[(1 S)-2-[[(...)
Affinity DataIC50: 203nMAssay Description:For the Bir2 assay, 12 nanomolar of 6× Histidine-tagged BIR2 domain (6× Histidine38 disclosed as SEQ ID NO: 25), corresponding to amino acids 174-256...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 66 total ) | Next | Last >>
Jump to: